8 Questions on Diabetes Drugs for Cardioprotection


Cardioprotective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) have been reported in a number of high-profile, landmark clinical trials.

Take this quick quiz to test your knowledge of key findings.